These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 22445095

  • 1. The PI3K/AKT/mTOR signalling pathway is active in salivary gland cancer and implies different functions and prognoses depending on cell localisation.
    Ettl T, Schwarz-Furlan S, Haubner F, Müller S, Zenk J, Gosau M, Reichert TE, Zeitler K.
    Oral Oncol; 2012 Sep; 48(9):822-30. PubMed ID: 22445095
    [Abstract] [Full Text] [Related]

  • 2. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P, Levidou G, Trigka EA, Prekete N, Karlou M, Thymara I, Sakellariou S, Fragkou P, Isaiadis D, Pavlopoulos P, Patsouris E, Saetta AA.
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [Abstract] [Full Text] [Related]

  • 3. Activation of the Akt-mTOR pathway and receptor tyrosine kinase in patients with solitary fibrous tumors.
    Yamada Y, Kohashi K, Fushimi F, Takahashi Y, Setsu N, Endo M, Yamamoto H, Tokunaga S, Iwamoto Y, Oda Y.
    Cancer; 2014 Mar 15; 120(6):864-76. PubMed ID: 24353015
    [Abstract] [Full Text] [Related]

  • 4. Immunohistochemical and molecular analysis of PI3K/AKT/mTOR pathway in esophageal carcinoma.
    Tasioudi KE, Sakellariou S, Levidou G, Theodorou D, Michalopoulos NV, Patsouris E, Korkolopoulou P, Saetta AA.
    APMIS; 2015 Aug 15; 123(8):639-47. PubMed ID: 25912437
    [Abstract] [Full Text] [Related]

  • 5. Association between high expression of phosphorylated Akt and mammalian target of rapamycin and improved survival in salivary gland adenoid cystic carcinoma.
    Ouyang DQ, Liang LZ, Ke ZF, Zheng GS, Weng DS, Yang WF, Su YX, Liao GQ.
    Head Neck; 2017 Jun 15; 39(6):1145-1154. PubMed ID: 28230926
    [Abstract] [Full Text] [Related]

  • 6. Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder.
    Sun CH, Chang YH, Pan CC.
    Histopathology; 2011 Jun 15; 58(7):1054-63. PubMed ID: 21707707
    [Abstract] [Full Text] [Related]

  • 7. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
    Trigka EA, Levidou G, Saetta AA, Chatziandreou I, Tomos P, Thalassinos N, Anastasiou N, Spartalis E, Kavantzas N, Patsouris E, Korkolopoulou P.
    Oncol Rep; 2013 Aug 15; 30(2):623-36. PubMed ID: 23728071
    [Abstract] [Full Text] [Related]

  • 8. Prognostic impact of the activation status of the Akt/mTOR pathway in synovial sarcoma.
    Setsu N, Kohashi K, Fushimi F, Endo M, Yamamoto H, Takahashi Y, Yamada Y, Ishii T, Yokoyama K, Iwamoto Y, Oda Y.
    Cancer; 2013 Oct 01; 119(19):3504-13. PubMed ID: 23861137
    [Abstract] [Full Text] [Related]

  • 9. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.
    Xu ZZ, Xia ZG, Wang AH, Wang WF, Liu ZY, Chen LY, Li JM.
    Ann Hematol; 2013 Oct 01; 92(10):1351-8. PubMed ID: 23636313
    [Abstract] [Full Text] [Related]

  • 10. Phosphorylated 4E-binding protein 1 (p-4E-BP1): a novel prognostic marker in human astrocytomas.
    Korkolopoulou P, Levidou G, El-Habr EA, Piperi C, Adamopoulos C, Samaras V, Boviatsis E, Thymara I, Trigka EA, Sakellariou S, Kavantzas N, Patsouris E, Saetta AA.
    Histopathology; 2012 Aug 01; 61(2):293-305. PubMed ID: 22690797
    [Abstract] [Full Text] [Related]

  • 11. Overexpression of T-cadherin inhibits the proliferation of oral squamous cell carcinoma through the PI3K/AKT/mTOR intracellular signalling pathway.
    Wang Q, Zhang X, Song X, Zhang L.
    Arch Oral Biol; 2018 Dec 01; 96():74-79. PubMed ID: 30195142
    [Abstract] [Full Text] [Related]

  • 12. Analysis of PI3K/AKT/mTOR signalling pathway in high risk neuroblastic tumours.
    Iżycka-Świeszewska E, Drożyńska E, Rzepko R, Kobierska-Gulida G, Grajkowska W, Perek D, Balcerska A.
    Pol J Pathol; 2010 Dec 01; 61(4):192-8. PubMed ID: 21290341
    [Abstract] [Full Text] [Related]

  • 13. Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors.
    Dworakowska D, Wlodek E, Leontiou CA, Igreja S, Cakir M, Teng M, Prodromou N, Góth MI, Grozinsky-Glasberg S, Gueorguiev M, Kola B, Korbonits M, Grossman AB.
    Endocr Relat Cancer; 2009 Dec 01; 16(4):1329-38. PubMed ID: 19620247
    [Abstract] [Full Text] [Related]

  • 14. Abnormal Protein Glycosylation and Activated PI3K/Akt/mTOR Pathway: Role in Bladder Cancer Prognosis and Targeted Therapeutics.
    Costa C, Pereira S, Lima L, Peixoto A, Fernandes E, Neves D, Neves M, Gaiteiro C, Tavares A, Gil da Costa RM, Cruz R, Amaro T, Oliveira PA, Ferreira JA, Santos LL.
    PLoS One; 2015 Dec 01; 10(11):e0141253. PubMed ID: 26569621
    [Abstract] [Full Text] [Related]

  • 15. Localisation of phosphorylated mTOR expression is critical to tumour progression and outcomes in patients with endometrial cancer.
    Yoshida Y, Kurokawa T, Horiuchi Y, Sawamura Y, Shinagawa A, Kotsuji F.
    Eur J Cancer; 2010 Dec 01; 46(18):3445-52. PubMed ID: 20926288
    [Abstract] [Full Text] [Related]

  • 16. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors.
    Endo M, Yamamoto H, Setsu N, Kohashi K, Takahashi Y, Ishii T, Iida K, Matsumoto Y, Hakozaki M, Aoki M, Iwasaki H, Dobashi Y, Nishiyama K, Iwamoto Y, Oda Y.
    Clin Cancer Res; 2013 Jan 15; 19(2):450-61. PubMed ID: 23209032
    [Abstract] [Full Text] [Related]

  • 17. The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance.
    Tapia O, Riquelme I, Leal P, Sandoval A, Aedo S, Weber H, Letelier P, Bellolio E, Villaseca M, Garcia P, Roa JC.
    Virchows Arch; 2014 Jul 15; 465(1):25-33. PubMed ID: 24844205
    [Abstract] [Full Text] [Related]

  • 18. [Recent studies on PI3K/AKT/mTOR signaling pathway in hematopoietic stem cells].
    Zhang YC, Cheng T, Yuan WP.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb 15; 21(1):245-9. PubMed ID: 23484729
    [Abstract] [Full Text] [Related]

  • 19. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
    Marzec M, Kasprzycka M, Liu X, El-Salem M, Halasa K, Raghunath PN, Bucki R, Wlodarski P, Wasik MA.
    Oncogene; 2007 Aug 16; 26(38):5606-14. PubMed ID: 17353907
    [Abstract] [Full Text] [Related]

  • 20. Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.
    Bitting RL, Armstrong AJ.
    Endocr Relat Cancer; 2013 Jun 16; 20(3):R83-99. PubMed ID: 23456430
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.